Nanomaterial-based drug delivery holds tremendous promise for improving targeting capacity, biodistribution,
and performance of therapeutic/diagnostic agents. Accelerating the clinical translation of current
nanomedicine requires an in-depth understanding of the mechanism underlying the dynamic interaction between
nanomaterials and cells in a physiological/pathophysiological-relevant condition. The introduction of the advanced
microfluidic platform with miniaturized, well-controlled, and high-throughput features opens new investigation
and application opportunities for nanomedicine evaluation. This review highlights the current state-of-theart
in the field of 1) microfluidic-assisted in vitro assays that are capable of providing physiological-relevant flow
conditions and performing high-throughput drug screening, 2) advanced organ-on-a-chip technology with the
combination of microfabrication and tissue engineering techniques for mimicking microenvironment and better
predicting in vivo response of nanomedicine, and 3) the integration of microdevice with various detection techniques
that can monitor cell-nanoparticle interaction with high spatiotemporal resolution. Future perspectives
regarding optimized on-chip disease modeling and personalized nanomedicine screening are discussed towards
further expanding the utilization of the microfluidic-based platform in assessing the biological behavior of nanomaterials.
Keywords: Nanomedicine, microfluidic, drug evaluation, organ-on-chip, nanoparticle, drug delivery.
Riaz N, Wolden SL, Gelblum DY, Eric J. Microfluidic device to control interstitial flow-mediated homotypic and heterotypic cellular communication. Lab Chip 2016; 118: 6072-8.
Oddo A, Peng B, Tong Z, et al. Advances in microfluidic blood–
brain barrier (BBB) models Trends Biotechnol 2019; S0167-7799: 30084-8.
Rights & PermissionsPrintExport